Current Edition


For Incyte’s eczema cream Opzelura, consumer complaint reveals ongoing quality woes, replacement backlog

When Gale Wild-Ebers, 62, ordered a second tube of Incyte’s topical eczema drug Opzelura in March, something appeared wrong with the product she received. Instead …

Continue Reading →

Pfizer’s Cibinqo snags FDA approval to challenge Sanofi and Regeneron’s Dupixent in eczema

Look out, Sanofi and Regeneron: Pfizer is on the scene in atopic dermatitis with another blockbuster-to-be. Friday, the FDA approved the New York drugmaker’s oral …

Continue Reading →
antibody drugs

China’s new NRDL; Biocon-Viatris biosimilar merger?; Avistone’s $200M series A

China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris are …

Continue Reading →